Nov 2, 2026
UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.
Dutch biotech UniQure submitted its Huntington's disease gene therapy to the FDA for approval after the agency reversed its earlier position on the experimental treatment, following an unusually turbulent development process.